Indwelling central venous access port insertion during bevacizumab-based therapy

Anti-Cancer Drugs

Volumn 21, Issue 7, 2010, Pages 704-707

  Grenader, Tal ^a   Goldberg, Anthony ^a   Verstandig, Anthony ^a   Shavit, Linda ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

bevacizumab; indwelling central venous catheters; port a cath

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CENTRAL VENOUS CATHETER; CLINICAL EVALUATION; COLON CANCER; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; HUMAN; INDWELLING CATHETER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 77954659237     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833a5c51     Document Type: Article

References (23)

1. Yeste Sánchez L, Galbis Caravajal JM, Fuster Diana CA, Moledo Eiras E. Protocol for the implantation of a venous access device (Port-A-Cath System). The complications and solutions found in 560 cases. Clin Transl Oncol 2006; 8:735-741.
2. Hurwitz H, Fehrenbacher L, NovotnyW, Cartwright T, Hainsworth J, HeimW, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
3. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697-3705.
4. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
5. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
6. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26:5422-5428.
7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-4740.
8. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. Surg Oncol 2005; 91:173-180.
9. D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007; 14:759-765.
10. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
11. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascularendothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165:35-52.
12. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002; 5:237-256.
13. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788-1795.
14. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomized phase-III NO16966 trial. Br J Cancer 2009; 101:1033-1038.
15. Sugrue MM, Purdie DM, Feng S, Flynn PJ, Grothey A, Sargent DJ, et al. Serious wound healing complications following surgery in patients with metastatic colorectal cancer receiving bevacizumab: results from the BRiTE observational cohort study (abstract). JCO 2008; 15S:4105.
16. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206:96-106.
17. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, et al. Preoperative bevacizumab does not significantly increase postoperative 706 Anti-Cancer Drugs 2010, Vol 21 No 7.
18. Complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26:5254-5260.
19. McNulty NJ, Perrich KD, Silas AM, Linville RM, Forauer AR. Implantable subcutaneous venous access devices: is port fixation necessary? A review of 534 cases. Cardiovasc Intervent Radiol 2009. [Epub ahead of print]
20. Titapiwatanakun R, Moir C, Pruthi RK, Stavlo PL, Schmidt KA, Rodriguez V. Central venous access devices for paediatric patients with haemophilia: a single-institution experience. Haemophilia 2009; 15:168-174.
21. Yip D, Funaki B. Subcutaneous chest ports via the internal jugular vein. A retrospective study of 117 oncology patients. Acta Radiol 2002; 43:371-375.
22. Starkhammar H, Bengtsson M. Totally implanted device for venous access. Experience in tumour patients. Acta Radiol Oncol 1985; 24:173-176.
23. Almhanna K, Pelley RJ, Thomas Budd G, Davidson J, Moore HC. Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series. Anticancer Drugs 2008; 19:217-219.